Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
REGULATORY
Novavax COVID-19 Jab OK’ed for 1st to 3rd Shot Use under Free Program
A Japanese health ministry panel on April 27 agreed to incorporate Novavax’s COVID-19 vaccine Nuvaxovid into Japan’s free emergency inoculation program for assumed use for the first to third inoculations. The jab had won regulatory approval earlier this month. Under…
To read the full story
Related Article
- Nuvaxovid Gets Label Update to Allow Primary Inoculations in Ages 12 and Older
July 21, 2022
- Japan Plans to Lower Minimum Age for Novavax Jab to 12
July 19, 2022
- Novavax Vaccine Officially Added to Japan’s Free COVID-19 Inoculation Program
May 26, 2022
- Japan Approves Novavax’s COVID-19 Vaccine; Distribution to Start in Late May
April 19, 2022
- Novavax COVID-19 Vaccine Clears MHLW Panel, Approval Expected Soon
April 19, 2022
- Japan to Start Distributing Novavax Jab from Late May, If Approved
April 7, 2022
- Novavax’s COVID-19 Vaccine Up for PAFSC Review on Regular Pathway
April 5, 2022
- Japan Secures 18 Million Extra Doses of Moderna Vaccines
December 27, 2021
- Novavax’s COVID-19 Vaccine Filed in Japan: Takeda
December 16, 2021
- Japan Strikes Deal for 150 Million Novavax Vaccine Doses, Supply Could Start Early Next Year
September 7, 2021
- Japan Secures Enough Doses for Booster Shots Next Year: Minister
August 18, 2021
- Takeda Launches Japan PI/II Trial of Novavax COVID-19 Vaccine
February 25, 2021
- Takeda Pairs with Novavax to Roll Out Coronavirus Vaccine in Japan, Wins 30 Billion Yen in Govt Funding
August 11, 2020
REGULATORY
- Japan Nudged to Probe Wide Gaps in Biosimilar Uptake
November 6, 2026
- Japan Eyes Multi-Year Investment Support for Wholesalers in FY2027 Budget
November 6, 2026
- Japan Poised to Broker Generic Firms’ Product Consolidation Talks
November 6, 2026
- Japan Issues Guidance on AI Model Use in Drug Manufacturing, Quality Control
November 6, 2026
- JPMA Urges Foreign Price Rule Overhaul to Address US MFN Policy: LDP Hearing
November 5, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…